Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Abstract Background Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently presented for generating neutralizing antibodies and as a model for new vac...

Full description

Bibliographic Details
Main Authors: Norma A. Valdez‑Cruz, Diego Rosiles-Becerril, Constanza E. Martínez-Olivares, Enrique García‑Hernández, Laura Cobos-Marín, Daniel Garzón, Francisco E. López-Salas, Guadalupe Zavala, Axel Luviano, Alejandro Olvera, Alejandro Alagón, Octavio T. Ramírez, Mauricio A. Trujillo‑Roldán
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Microbial Cell Factories
Online Access:https://doi.org/10.1186/s12934-024-02320-5

Internet

https://doi.org/10.1186/s12934-024-02320-5

Similar Items